Diagnostics

Medtronic And Lilly Form Alliance To Provide Solutions For Diabetes Management

Two of the most recognized names in diabetes management - Medtronic, Inc. (NYSE: MDT) and Eli Lilly and Company (NYSE: LLY) - announced a strategic marketing collaboration to bolster each company"s commitment to help people with diabetes manage teir blood sugar using insulin therapy. Working collaboratively with health care professionals, Medtronic and Lilly marketing and sales operations in the United States will work to improve the delivery of diabetes educatio for insulinТЂтtaking patients and their caregivers. This includes the development of new educational res and classes around the initiation and intensive management of insuln, insulin pump therapy and continuous glucose monitoring (CGM). The alliance combines the insulin expertise of Lilly - a worldwide leader in diabetes treatment, research and education - with the advanced diabetes technologies of Medtronic, the world"s largest manufacturer of insulin pumps and CGM, and maker of the world"s only integrated diabetes management system that combines the power of insulin pump therapy with CGM. "Medtronic and Lilly are joining together to help improve patient access to highТЂтquality diabetes education," said Chris O"Connell, president of the Diabetes business unit and senior vice president at Medtronic. "Because diabetes management is complicated, it is crucial that physicians and patients have the best access to information and educational res. This collaboration will generate greater awareness and enable more people to benefit from the latest educational tools regardig insulin pump therapy and continuous glucose monitoring." "People with diabetes have numerous treatment options and devices to help manage blood sugar, but physicians and patients need res and solutions to integrate these improvements into realТЂтworld therapy," said Matt Beebe, Diabetes brand leader, Lilly USA, LLC. "With this alliance, Lilly and Medtronic hope to create integrated solutions to address challenges for people taking insulin who need optimal glyceic control. By joining forces, we will help make insulin therapy more achievable by offering new educational materials and res that help make insulin pmp therapy fit into patients" lives." Both companies are dedicated to improving the overall patient experience and bring trusted reputations along with a history of irsts in diabetes care. Medtronic has been wellТЂтestablished as the leader in insulin delivery innovation since it introduced its first insulin pump in 1983, and has been improving on the technology for more than 25 years. Medtronic continued to innovate with the first CGM system approved for physician use in 1999, the first patientТЂтuse CGM in 2003 and the most advanced WebТЂтbased therapy management system in 2004. Lilly has long been the leading innovator in insulin therapy; Lilly introduced the world"s first insulin for public use in 1923 and has continued to introduce advances in diabetes therapy ver the next 85 years. About Diabetes According to the Centers for Disease Control and Prevention, diabetes affects nearly 24 million Americans; of that, nearly oneТЂтquarter, or nearly six million people, do not know they have the disease.1 Diabetes is the sixth leading cause of death in the United States and costs approximately $174 billion per year in direct and indirect medical expenses.1,2 About Lilly Diabetes For more than 85 years, Lilly has been a worldwide leader in pioneering industryТЂтleading solutions to support people living with and treating diabetes. Lilly introduced the world"s first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy ТЂтТЂт practical tools, education and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journey of each person living with or treating diabetes inspires ours. For more information, visit http://www.lillydiabetes.com About Eli Lilly and Company Lilly, a leading innovationТЂтdriven corporation, is developing a growing portfolio of firstТЂтinТЂтclass and bestТЂтinТЂтclass pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with minent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers ТЂтТЂт through medicines and information ТЂтТЂт for some of the worldКрs most urgent medical needs. Information about Lilly is available at http://www.lilly.com. About the Diabetes Business at Medtronic The Diabetes business at Medtronic is the world leader in advanced diabetes management solutions, including integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems and therapy management software. References 1 Centers for Disease Control and Prevention (CDC). National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Rev ed. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008 2 American Diabetes Association. Direct and indirect costs of diabetes in the United States. Available here. Accessed January 16, 2009 Medtronic

Add your comment:

Name:
Site address:	http://
Your message:
Enter today\\\\'s date, 2 digits (spam protection):